Talazoparib
Talazoparib
Talazoparib (pronounced ta-LAZ-oh-par-ib) is a medication used in the treatment of certain types of breast cancer. It is a type of PARP inhibitor, which works by blocking the action of an enzyme called poly (ADP-ribose) polymerase (PARP) that is involved in DNA repair. By inhibiting PARP, talazoparib can cause cancer cells to die.
Etymology
The name "Talazoparib" is derived from the combination of letters from the words "TAlazopARIB". The prefix "Tal-" is an arbitrary designation, while "-azoparib" is a common suffix for PARP inhibitors.
Usage
Talazoparib is used to treat adults with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. Patients must be selected for therapy based on an FDA-approved companion diagnostic for talazoparib.
Related Terms
- PARP inhibitor: A type of drug that blocks the action of PARP and causes cancer cells to die.
- BRCA mutation: A mutation in either of the BRCA1 and BRCA2 genes, which are tumor suppressor genes. Mutations in these genes can lead to the development of hereditary breast and ovarian cancer.
- HER2-negative: A term used to describe a type of breast cancer that tests negative for a protein called human epidermal growth factor receptor 2 (HER2). HER2-negative breast cancers can be more difficult to treat than HER2-positive breast cancers.
Side Effects
Common side effects of talazoparib include fatigue, anemia, nausea, neutropenia, headache, thrombocytopenia, vomiting, alopecia, diarrhea, and decreased appetite.
External links
- Medical encyclopedia article on Talazoparib
- Wikipedia's article - Talazoparib
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski